Phase II trial of Bevacizumab with Dose-dense Paclitaxel as First-Line Treatment in Patients with Advanced Ovarian Cancer

OBJECTIVES: To assess the tolerability and efficacy of bevacizumab with carboplatin and weekly paclitaxel as first-line adjuvant therapy for advanced stage ovarian cancer. METHODS: After IRB approval, this single-institution, phase II study enrolled patients with stage III or IV epithelial ovarian c...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Gynecol Oncol
Main Authors: Fleming, Nicole D., Coleman, Robert L., Tung, Celestine, Westin, Shannon N., Hu, Wei, Sun, Yunjie, Bhosale, Priya, Munsell, Mark F., Sood, Anil K.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5605462/
https://ncbi.nlm.nih.gov/pubmed/28774461
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2017.07.137
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados